Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

By Pratley Richard E.   Reusch Jane E.-B.   Fleck Penny R.   Wilson Craig A.   Mekki Qais  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2361-2371

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1198-1201

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial

By Kaku Kohei  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1111-1119

Informa Healthcare

Access to resources Recommend Favorite

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 136-144

John Wiley & Sons Inc

Access to resources Recommend Favorite